Hepatitis C treatment program in Maputo, Mozambique, the challenge of genotypes and key populations: A 5-year retrospective analysis of routine programmatic data.
developing countries
genotype
harm reduction
hepatitis C
retrospective studies
Journal
Health science reports
ISSN: 2398-8835
Titre abrégé: Health Sci Rep
Pays: United States
ID NLM: 101728855
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
08
11
2022
revised:
10
03
2023
accepted:
13
03
2023
medline:
4
4
2023
entrez:
3
4
2023
pubmed:
4
4
2023
Statut:
epublish
Résumé
Hepatitis C (HCV) programs face challenges, especially linked to key populations to achieve World Health Organization (WHO) goals of eliminating hepatitis. Médecins Sans Frontières and Mozambique's Ministry of Health first implemented HCV treatment in Maputo, in 2016 and harm reduction activities in 2017. We retrospectively analyzed routine data of patients enrolled between December 2016 and July 2021. Genotyping was systematically requested up to 2018 and subsequently in cases of treatment failure. Sustainable virological response was assessed 12 weeks after the end of treatment by sofosbuvir-daclatasvir or sofosbuvir-velpatasvir. Two hundred and two patients were enrolled, with 159 (78.71%) males (median age: 41 years [interquartile range (IQR): 37.10, 47.00]). Risk factors included drug use (142/202; 70.29%). One hundred and eleven genotyping results indicated genotype 1 predominant (87/111; 78.37%). Sixteen patients presented genotype 4, with various subtypes. The people who used drugs and HIV coinfected patients were found more likely to present a genotype 1. Intention-to-treat analysis showed 68.99% (89/129) cure rate among the patients initiated and per-protocol analysis, 88.12% (89/101) cure rate. Nineteen patients received treatment integrated with opioid substitution therapy, with a 100% cure rate versus 59.37% (38/64) for initiated ones without substitution therapy ( We found varied genotypes, including some identified as difficult-to-treat subtypes. People who used drugs were more likely to present genotype 1. In addition, opioid substitution therapy was key for these patients to achieve cure. Access to second-generation direct-acting antivirals (DAAs) and integration of HCV care with harm reduction are crucial to program effectiveness.
Sections du résumé
Background and Aims
UNASSIGNED
Hepatitis C (HCV) programs face challenges, especially linked to key populations to achieve World Health Organization (WHO) goals of eliminating hepatitis. Médecins Sans Frontières and Mozambique's Ministry of Health first implemented HCV treatment in Maputo, in 2016 and harm reduction activities in 2017.
Methods
UNASSIGNED
We retrospectively analyzed routine data of patients enrolled between December 2016 and July 2021. Genotyping was systematically requested up to 2018 and subsequently in cases of treatment failure. Sustainable virological response was assessed 12 weeks after the end of treatment by sofosbuvir-daclatasvir or sofosbuvir-velpatasvir.
Results
UNASSIGNED
Two hundred and two patients were enrolled, with 159 (78.71%) males (median age: 41 years [interquartile range (IQR): 37.10, 47.00]). Risk factors included drug use (142/202; 70.29%). One hundred and eleven genotyping results indicated genotype 1 predominant (87/111; 78.37%). Sixteen patients presented genotype 4, with various subtypes. The people who used drugs and HIV coinfected patients were found more likely to present a genotype 1. Intention-to-treat analysis showed 68.99% (89/129) cure rate among the patients initiated and per-protocol analysis, 88.12% (89/101) cure rate. Nineteen patients received treatment integrated with opioid substitution therapy, with a 100% cure rate versus 59.37% (38/64) for initiated ones without substitution therapy (
Conclusion
UNASSIGNED
We found varied genotypes, including some identified as difficult-to-treat subtypes. People who used drugs were more likely to present genotype 1. In addition, opioid substitution therapy was key for these patients to achieve cure. Access to second-generation direct-acting antivirals (DAAs) and integration of HCV care with harm reduction are crucial to program effectiveness.
Identifiants
pubmed: 37008813
doi: 10.1002/hsr2.1165
pii: HSR21165
pmc: PMC10061494
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e1165Informations de copyright
© 2023 The Authors. Health Science Reports published by Wiley Periodicals LLC.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
J Hepatol. 2021 Jun;74(6):1472-1482
pubmed: 33716089
Virology. 2014 Sep;464-465:233-243
pubmed: 25105489
Harm Reduct J. 2019 Apr 11;16(1):28
pubmed: 30975139
J Hepatol. 2020 Nov;73(5):1170-1218
pubmed: 32956768
Lancet Gastroenterol Hepatol. 2021 Sep;6(9):693-694
pubmed: 34391525
Lancet Gastroenterol Hepatol. 2022 May;7(5):426-445
pubmed: 35303490
AIDS. 2008 Jul 11;22(11):1247-56
pubmed: 18580603
JAMA Intern Med. 2022 May 1;182(5):494-502
pubmed: 35285851
Hepatology. 2015 Jan;61(1):77-87
pubmed: 25069599
Top Antivir Med. 2017 Jul/Aug;25(3):103-109
pubmed: 28820725
J Hepatol. 2019 Dec;71(6):1099-1105
pubmed: 31400349
J Hepatol. 2016 Dec;65(6):1094-1103
pubmed: 27520879
AIDS. 2019 Feb 1;33(2):353-355
pubmed: 30475267
J Hepatol. 2021 Aug;75(2):462-473
pubmed: 33974951
Drug Resist Updat. 2018 Mar;37:17-39
pubmed: 29525636
J Hepatol. 2018 Aug;69(2):461-511
pubmed: 29650333
BMC Infect Dis. 2019 Dec 2;19(1):1022
pubmed: 31791273
BMC Public Health. 2021 Jan 15;21(1):146
pubmed: 33451344
J Hepatol. 2020 Mar;72(3):583-584
pubmed: 31836263
J Hepatol. 2019 Dec;71(6):1070-1072
pubmed: 31648816
HIV Med. 2014 Jan;15(1):30-9
pubmed: 24007567
J Clin Gastroenterol. 2004 Jan;38(1):68-71
pubmed: 14679330
J Hepatol. 2017 Jan;66(1):153-194
pubmed: 27667367
Bull World Health Organ. 2018 Jan 1;96(1):51-58
pubmed: 29403100
Int J Drug Policy. 2013 Jan;24(1):78-81
pubmed: 23036650
Rev Soc Bras Med Trop. 2008 Sep-Oct;41(5):518
pubmed: 19009199
Drug Alcohol Depend. 2012 Jun 1;123(1-3):122-31
pubmed: 22138540
J Viral Hepat. 2007 Jul;14(7):460-7
pubmed: 17576387
Hepatology. 2019 Apr;69(4):1426-1441
pubmed: 30387174
Lancet Gastroenterol Hepatol. 2021 Oct;6(10):778-780
pubmed: 34384530
J Hepatol. 2020 Oct;73(4):794-799
pubmed: 32470499
Int J Drug Policy. 2021 Apr;90:103095
pubmed: 33429163
Lancet Gastroenterol Hepatol. 2022 Jun;7(6):542-551
pubmed: 35248212
JAMA Intern Med. 2022 May 1;182(5):502
pubmed: 35285866
Lancet Gastroenterol Hepatol. 2021 Jun;6(6):448-458
pubmed: 33865507
JHEP Rep. 2022 Feb 24;4(5):100462
pubmed: 35434589
Lancet Gastroenterol Hepatol. 2019 Feb;4(2):119-126
pubmed: 30552056
Lancet Gastroenterol Hepatol. 2021 May;6(5):371-380
pubmed: 33743883